Publications

June 2020
Case

Breakthroughs at Blueprint Medicines

By: Richard G. Hamermesh, Kathy Giusti and Susie L. Ma

Precision medicine company Blueprint Medicines was building a successful track record for bringing drug therapies to market 40% faster than average. The company had spent $40 million dollars and two years building a compound library that became its drug development... View Details

Keywords: Precision Medicine; Cancer; Biotechnology; Drug Development; Strategy; Expansion; Science; Genetics; Information Technology; Entrepreneurship; Organizational Culture; Management; Growth and Development; Pharmaceutical Industry; United States; Cambridge; Massachusetts

16 Aug 2016
Blog Post

Health Care Club: Summer Spotlight

Tell us about where you’re working this summer. I am at Shire, in their Business Development group located in Lexington, MA (soon moving to Kendall Square). Shire is considered “Big Pharma” which basically means it is one of the larger View Details

Keywords: Health Care

February 2010
Supplement

Organization and Strategy at Millennium (B)

By: Julie M. Wulf and Scott Waggoner

This case examines Millennium's strategic and organizational responses to the rapid evolution of the biopharmaceutical industry. In the early 2000s, as Millennium's competitive advantage in early-stage research slipped away and its losses mounted, founder CEO Mark... View Details

Keywords: Leading Change; Transformation; Decision Choices and Conditions; Crisis Management; Competitive Advantage; Commercialization; Selection and Staffing; Product Development; Organizational Change and Adaptation; Pharmaceutical Industry

2014
Working Paper

Visualizing and Measuring Software Portfolio Architectures: A Flexibility Analysis

By: Robert Lagerstrom, Carliss Y. Baldwin, Alan MacCormack and David Dreyfus

In this paper, we test a method for visualizing and measuring software portfolio architectures and use our measures to predict the costs of architectural change. Our data is drawn from a biopharmaceutical company, comprising 407 architectural components with 1,157... View Details

Keywords: Design Structure Matrices; Software Architecture; Flexibility; Software Application Portfolio; Complexity; Applications and Software; Forecasting and Prediction

Amitabh Chandra is the Henry and Allison McCance Family Professor of Business Administration at Harvard Business School where he is the Faculty Chair of the joint View Details

September 2021
Article

Trials and Terminations: Learning from Competitors' R&D Failures

By: Joshua L. Krieger

I analyze project continuation decisions where firms may resolve uncertainty through news about competitors' research and development (R&D) failures, as well as through their own results. I examine the trade-offs and interactions between product-market competition and... View Details

Keywords: Research and Development; Projects; Failure; Decision Making; Learning

For the first time in anybody's memory we're starting to see the biopharmaceutical industry and the medical industry at large affected by a recession. I think there are a couple of reasons. One is very high unemployment, and every time the unemployment rate goes up,... View Details

November 2016
Article

Spatial Organization of Firms and Location Choices Through the Value Chain

By: Juan Alcacer and Mercedes Delgado

We explore the impact of geographically bounded, intra-firm linkages (internal agglomerations) and geographically bounded, inter-firm linkages (external agglomerations) on firms' location strategies. Using data from the Census Bureau's Longitudinal Business Database,... View Details

Keywords: Location Choices; Agglomeration Economies; Value Chain; Organization Theory; Geographic Location; Business Strategy

September–October 2020
Article

The Past, Present, and (Near) Future of Gene Therapy and Gene Editing

By: Julia Pian, Amitabh Chandra and Ariel Dora Stern

Emerging gene therapy and gene-editing technologies will have a growing impact on patient lives and health-care delivery. We analyzed a decade of data on clinical trials and venture capital investments to understand the likely trajectory of genetically focused... View Details

Keywords: Gene Therapy; Gene Editing; Impact; Health Care and Treatment; Technological Innovation; Health Testing and Trials; Venture Capital; Change

Article

Lessons From Hollywood: A New Approach To Funding R&D

By: Gary P. Pisano and Andrew W. Lo

Companies find it increasingly difficult to justify long-term, risky R&D investments—particularly in science-based fields such as biotechnology, advanced materials, and energy. We argue in this article that the traditional venture model has limits for such investments... View Details

Keywords: Financial Innovation; Financial Strategy; Project Management; R＆D; Start-up; Innovation Strategy; Business Model; Research and Development; Financial Management; Risk Management; Strategy

November 2016
Case

QuintilesIMS: Biosimilar Marketing in England

By: John A. Quelch and Emily C. Boudreau

QuintilesIMS was a leading healthcare consulting firm best known for its data and information offerings as well as its market research and management consulting services for life science companies. By 2015, the company was expanding beyond the biopharmaceutical... View Details

Keywords: Health; Pharmaceutical Industry; Biotech; Marketing; Health Care and Treatment; Biotechnology Industry; England

2013
Working Paper

Visualizing and Measuring Enterprise Architecture: An Exploratory BioPharma Case

By: Robert Lagerstrom, Carliss Baldwin, Alan MacCormack and David Dreyfus

We test a method that was designed and used previously to reveal the hidden internal architectural structure of software systems. The focus of this paper is to test if it can also uncover new facts about the components and their relationships in an enterprise... View Details

Keywords: Complexity; Applications and Software; Product Design; Pharmaceutical Industry

September 2022
Article

Giving a Buck or Making a Buck? Donations by Pharmaceutical Manufacturers to Independent Patient Assistance Charities

By: Leemore Dafny, Christopher Ody and Teresa Rokos

The federal Anti-Kickback Statute prohibits biopharmaceutical manufacturers from directly covering Medicare enrollees’ out-of-pocket spending for the drugs they manufacture, but manufacturers may donate to independent patient assistance charities and earmark donations... View Details

Keywords: Cost Sharing; Prescription Drugs; Drug Spending; Medicare; Dual Eligibility; Cost; Health Care and Treatment; Philanthropy and Charitable Giving; Pharmaceutical Industry

Register to Read

09 Apr 2014
Working Paper Summaries

Visualizing and Measuring Software Portfolio Architectures: A Flexibility Analysis

Keywords: by Robert Lagerstrom, Carliss Y. Baldwin, Alan MacCormack & David Dreyfus; Video Game; Web Services

Spatial Organization of Firms

We explore the impact of geographically bounded intra-firm spillovers (internal agglomeration economies) and geographically bounded inter-firm spillovers (external agglomeration economies) on firms’ location strategies. Using data from the Census Bureau’s Longitudinal... View Details

October 2024
Case

Parexel: Scaling Up and Industry Dynamics

By: Regina E. Herzlinger and Ben Creo

Through the lens of biopharmaceutical contract research organization (CRO) PAREXEL, this case traces the evolution of the firm as it reinvents itself in response to the transformation of the CRO sector from a small, secondary cluster of firms into a major player with... View Details

Keywords: Research; Innovation and Invention; Business Model; Transformation; Globalization; Information Technology; Competitive Advantage; Pharmaceutical Industry

August 2023
Case

Constellation Pharmaceuticals: Corporate Development at a Novel Therapeutic Company

By: Satish Tadikonda and Brad Prosek

Constellation Pharmaceuticals was a company focused on epigenetic therapies for cancer patients. Despite a promising start and an early deal with a leading biopharma company, the company weathered twin setbacks in the end of a major research collaboration and the... View Details

Keywords: Mergers and Acquisitions; Health Care and Treatment; Organizational Change and Adaptation; Research and Development; Business Strategy; Partners and Partnerships; Goals and Objectives; Pharmaceutical Industry; United States

2010
Working Paper

Boundary Spanning in a For-profit Research Lab: An Exploration of the Interface Between Commerce and Academe

By: Christopher C. Liu and Toby E. Stuart

In innovative industries, private-sector companies increasingly are participants in open communities of science and technology. To participate in the system of exchange in such communities, firms often publicly disclose what would otherwise remain private discoveries.... View Details

Keywords: For-Profit Firms; Higher Education; Information Publishing; Innovation and Invention; Science-Based Business; Social and Collaborative Networks; Boundaries; Biotechnology Industry; Pharmaceutical Industry